Fed hike bets are repricing fast and the ECB meets Thursday — the Nasdaq 100's 27,750 support will show whether this correction deepens.
After accumulating approximately 16% gains since 31 March in an almost uninterrupted advance, the S&P 500 suffered its steepest weekly decline since last May, falling 2.6%. Friday's blowout non-farm payrolls data catalysed the selloff, as the surge in Fed rate hike expectations weighed on the stretched valuations of growth stocks. The pullback was concentrated in technology — the Nasdaq 100 fell 4.5%, while the Dow Jones slipped just 0.3%, as investors rotated into value and cyclical sectors.
Despite the sharp moves, a correction of this magnitude following a sustained advance is consistent with healthy market dynamics — corporate fundamentals remain solid. Risks linger, however: forced unwinding of leveraged positions could amplify near-term volatility, while upcoming inflation prints may push bond yields higher, applying additional pressure on growth stock valuations.
Technology's weakness predated Friday. Broadcom's second-quarter results — revenue of US$22.2 billion, up 48% YoY — beat expectations, yet its third-quarter AI semiconductor guidance of US$16 billion missed the US$17.2 billion consensus, sending shares down 13.7% for the week. Even so, US$16 billion would represent over 200% YoY growth — an acceleration in demand. The deeper concern is whether elevated market expectations can continue to be met, particularly given Broadcom's chief executive flagging that Google would diversify its chip suppliers and that rapid AI revenue growth is compressing margins.
Qualcomm and Intel fell 14.0% and 13.5% respectively following Nvidia's announcement at Computex of its RTX Spark chip, co-developed with Microsoft, which directly targets the Windows laptop market both companies had been building towards.
Humana surged 14.6%, helping healthcare outperform. The managed care company reaffirmed its full-year earnings guidance and received a wave of analyst upgrades. The consensus views 2026 as an earnings trough ahead of a Medicare Advantage margin recovery.
After an advance of over 30% since late March, the US Tech 100 index has encountered a material pullback towards immediate support near 28,567. Failure to hold above this level may trigger further declines towards the 38.2% Fibonacci retracement of the up-wave, near 27,750 — a level that also coincides with a 10% correction from the peak of 30,759. As long as the index trades above the 200-day moving average (MA), the medium-term uptrend remains intact, with potential to re-challenge the historic peak.
The Hang Seng Index fell 0.9% last week, relatively insulated from the global AI selloff but weighed down by a regulatory headwind for Hong Kong's financial sector.
Concerns over cross-border capital controls, which had centred on brokers and banks, spread to insurers after China's securities regulator cracked down on unlicensed offshore brokers on 22 May, prompting banks to tighten scrutiny on mainland account openings. AIA bore the heaviest impact, falling 10.0% on the week, as mainland Chinese visitors purchasing Hong Kong-based insurance policies represent a substantial portion of its new premium income.
Meituan rebounded 8.9% after first-quarter results beat expectations. Operating losses narrowed from RMB 16.1 billion in the fourth quarter of 2025 to RMB 6.5 billion. Management signalled the food delivery subsidy war may be past its peak following regulatory intervention, raising hopes for a return to breakeven in the second quarter.
A weekly close below 25,000 indicates that the technical momentum of the Hang Seng Index remains weak. The index is currently just above support near 24,900; failure to hold could drive it further towards 24,700. The 200-day MA and the local high near 26,050 represent major resistance. A break above that level would allow the index to break out of its sideways trend.
Japan's foreign currency reserves fell by a record US$75.5 billion in May to US$1.09 trillion, the largest monthly decline on record. Foreign securities holdings dropped US$75.6 billion, a figure closely matching the Ministry of Finance's reported ¥11.7 trillion in yen-buying intervention during the month. While the Ministry does not provide a detailed breakdown of foreign reserve securities, economists estimate that roughly 70% consists of US Treasuries. For context, Japan spent ¥15.3 trillion defending the yen across the entirety of 2024, when USD/JPY also tested the 160 level.
The scale of the May operation proved insufficient. USD/JPY rose 0.7%, creeping back above 160 last week despite renewed verbal warnings from Finance Minister Katayama. The market reaction is aligned with our view that yen weakness cannot be sustainably reversed without a credible and sustained shift in monetary policy.
That shift may now be at hand. Bank of Japan (BoJ) Governor Ueda delivered a hawkish pivot on Wednesday, abandoning previous ambiguity on supply shocks and warning the BoJ may no longer look through war-driven inflation if second-round effects take hold. Markets priced a June hike to 1% — a level not seen since 1995 — at approximately 80% probability. A June hike alone is unlikely to reverse the yen's weakening trend. What markets need is a credible commitment to further tightening; without that, intervention amounts to little more than a holding action against a structural trend.
The technical picture remains unfavourable for the yen. USD/JPY is trading well above its 200-day MA, indicating a strong medium-term uptrend. Unless the pair falls below 155.5, the trend is unlikely to reverse. The resistance zone near 160–161 reflects both technical factors and the potential for government intervention, while immediate support can be found near 158.5.
China's trade figures on Tuesday open a week dominated by inflation data and central bank policy.
Exports surged 14.1% YoY in April, well above expectations, as overseas buyers stockpiled goods ahead of anticipated supply disruptions. Whether that momentum holds — or a pullback in front-loaded demand sees growth moderate — will be closely watched. Import figures deserve equal attention: with retail sales rising just 0.2% YoY in April, the weakest reading since December 2022, a further softening would reinforce structural demand concerns and raise pressure on Beijing for more targeted stimulus.
Inflation data from China and the US follow on Wednesday. US headline inflation has already climbed to 3.8% YoY, and economists warn that second-round effects — transport costs, food price pass-through and elevated expectations — typically take months to materialise fully. Strategic oil reserve releases may be dampening rather than eliminating the supply shock, suggesting the peak may not yet be in sight.
Thursday's ECB decision is near-certain: markets price a 99% probability of a 25-basis-point hike to 2.25%. Widely framed as an insurance hike to pre-empt second-round risks, President Lagarde's guidance on the path forward will be the key market-moving element.
Oracle reports on Wednesday amid scrutiny over whether its US$50 billion annual capital expenditure commitment can convert a record backlog into revenue and free cash flow. Adobe follows on Thursday, with its stock down almost 30% this year as investors weigh whether generative AI rivals are structurally undermining demand for its core products.
(All times in GMT+8)
Source: Trading Economics, Nasdaq, LSEG (as of 7 June 2026)
This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.